AirSculpt (AIRS) Q2 2026 Earnings Call Transcript
AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the combination of (1) FY adjusted EBITDA guidance reduced by $5M due to planned marketing investment, (2) Q3 revenue expected down single digits, and (3) continued stabilization signals via same-center case growth and debt reduction.
Market read
Traders can reassess the near-term margin outlook versus longer-term growth investment, using the explicit guidance ranges and the stated drivers.
What to watch
The partnership to offer AlloClae and the expanded skin excision footprint could be early-cycle catalysts, but the article does not quantify incremental revenue or margin contribution from these initiatives.
Background
AirSculpt Technologies held its Q2 2026 earnings call, covering operating metrics, balance sheet actions, and updated full-year guidance.
Ticker impact
AirSculpt reported Q2 revenue of $42.9M, guided FY revenue to $151M-$157M, and cut FY adjusted EBITDA guidance due to an added $5M marketing investment.
Likely choppy reaction, with upside if investors buy the brand-funnel thesis and downside if they focus on Q3 down-single-digits and EBITDA pressure.
The article provides multiple decision-relevant datapoints: Q2 results, revised FY adjusted EBITDA range, Q3 revenue outlook, and explicit linkage of the EBITDA guide reduction to incremental marketing spend.
Market effects
Highlights how GLP-1-driven demand is being monetized via both surgical and non-surgical offerings, with marketing spend as the key lever.
No specific regional impact disclosed.
No explicit global macro or international expansion details beyond the GLP-1 demographic framing.
Counterpoint
Investors may treat the marketing-driven EBITDA guide cut as evidence of weaker underlying demand, with brand spend masking slower conversion rather than improving it.
Key entities
- companyAirSculpt Technologies, Inc.
Reported Q2 2026 results and updated FY 2026 guidance, including a marketing-driven reduction to adjusted EBITDA outlook.
- executiveYogesh Jashnani
CEO who discussed moderating sales trends into July and the GLP-1 demand outlook.
- executiveMichael Arthur
CFO who described the updated 2026 outlook assumptions and refinancing term-sheet activity.
- partnerTiger Aesthetics
Named partner in a deal to offer AlloClae starting later in the quarter.
